BioSpace News Archive

KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), today announced that the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of Corium’s product ADLARITY® (donepezil transdermal system) by the U.S. Food and Drug Administration (FDA) on March 11, 2022.

Biogen announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET.

Applied UV, Inc. announces that Keith Frein, the Company’s VP of International Sales, will be presenting and showcasing the Company’s patented, research backed Airocide and Scientific Air Management air purification products at Hotels, Restaurants and Catering (HRC) 2022 in London, UK March 21-23, 2022.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule.

Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, is adding two new innovations to its kinematically advanced and proven ATTUNE™ Knee portfolio: the ATTUNE™ Cementless Fixed Bearing Knee with AFFIXIUM™ 3DP Technology and the ATTUNE™ Medial Stabilized Knee System.

Alltrna, a Flagship Pioneering company unlocking transfer RNA biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, announced the formation of Alltrna’s Scientific Advisory Board with leading experts in RNA biology and therapeutics.

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).

Moderna, Inc. today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna’s COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of 2022.